BRASILIA, Jan 8 (Reuters) - Brazilian health regulator Anvisa said on Friday that the Janssen unit of Johnson & Johnson had reported an adverse event suffered by a Brazilian volunteer in a Phase III trial for its COVID-19 vaccine.
Anvisa said Janssen and researchers found that the adverse event was not related to the vaccine. The agency said the trial will not have to be suspended, given that they were no longer recruiting new volunteers. (Reporting by Ricardo Brito Writing by Anthony Boadle Editing by Brad Haynes)
Our Standards: The Thomson Reuters Trust Principles.